Document |
Document Title |
WO/2019/097539A1 |
The present invention discloses cost-effective, industrially efficient and safe process synthesis of levomilnacipran that is devoid of 1-phenyl-1- diethylaminocarbonyl-2- chloromethylcyclopropane.
|
WO/2019/096325A1 |
The present invention relates to a bisamide complex, and a method for quickly detecting organophosphate and carbamate pesticides. The complex prepared in the present invention can effectively detect trace quantities of organophosphate an...
|
WO/2019/091975A1 |
The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.
|
WO/2019/081972A1 |
Preparation of a salt of 4-nitrophenyl ethylamine with (R)-mandelic acid and its use for the synthesis of mirabegron is disclosed. 4-Nitrophenyl ethylamine (1) is prepared by reduction of 4-nitrobenzyl cyanide (7) in a solvent with the u...
|
WO/2019/077104A1 |
The present invention relates to a process for synthesis of a compound according to Formula (A): wherein R1 is a substituted or unsubstituted aryl having 6 to 20 carbon atoms; preferably substituted or unsubstituted phenyl; R2 is a strai...
|
WO/2019/072864A1 |
The present invention pertains to a process for the preparation of polymorph form X of agomelatine, which comprises providing agomelatine, and crystallizing agomelatine in the presence of at least one of an acid and a salt thereof, and t...
|
WO/2019/074158A1 |
The present invention relates to a novel pseudoceramide compound and a use thereof. The pseudoceramide of the present invention has anti-oxidizing, anti-inflammatory, whitening, and moisturizing effects, is economical through a simple sy...
|
WO/2019/066644A1 |
The invention relates to the field of medicinal chemistry, more in particular to methods for providing highly pure, pharmaceutical grade synthetic Palmitoylethanolamine (PEA), to pure PEA preparations obtainable thereby, and the uses the...
|
WO/2019/044946A1 |
A method for producing a compound represented by formula (C), the method comprising a step for converting a compound represented by formula (B) (wherein R1 represents an amino group protected by a protecting group) by intramolecular cycl...
|
WO/2019/042086A1 |
The present invention discloses a method and a device for purifying 2-nitro-4-acetamidoanisole and a product purified thereby. The 2-nitro-4-acetamidoanisole is prepared by using p-acetaminoanisole as a raw material to perform mixed acid...
|
WO/2019/038638A1 |
Disclosed herein, in part, are processes of large scale purification of a L- dopamide pharmaceutically acceptable salt and processes of making a purified pharmaceutically acceptable L-dopamide and pharmaceutically acceptable L-dopamide s...
|
WO/2019/035453A1 |
Provided is a catalyst represented by general formula (1). In general formula (1), R1-R14 each independently represent a hydrogen atom or a substituent.
|
WO/2019/028198A1 |
Methods may include quantifying the concentration of residual free amine and/or free carboxylic acid in a product mixture prepared from a reaction of a multireactive species and a fatty reagent; verifying that the concentration for the f...
|
WO/2019/022203A1 |
The present invention provides: an aromatic amine compound capable of satisfactorily forming a cured product having exceptional alkali resistance by reaction with an epoxy compound; a curing agent for an epoxy compound, the curing agent ...
|
WO/2019/010016A1 |
There is disclosed a process for the production of long chain amino acid and long chain dibasic acid, comprising: (1) reacting long chain keto fatty acid with hydroxylamine or subjecting keto fatty acid to an ammoximation reaction to yie...
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
WO/2019/002042A1 |
The present invention relates to a method for preparing substituted 4-aminoindane derivatives of the general formula (I) by rearrangement of compounds of the formula (II) in HF, wherein R1, R2, R3, R4, and R5 have the definitions as spec...
|
WO/2018/233562A1 |
The present invention relates to an intermediate for preparing oseltamivir and an isomer thereof. The intermediate of the present invention is prepared by means of neighboring group participation at room temperature under the conditions ...
|
WO/2018/228546A1 |
Disclosed is a highly efficient contrast agent synthesizing method, comprising the following steps: (I) preparing an intermediate mixture of a compound represented by formula (II) and a compound represented by formula (I) and/or formula ...
|
WO/2018/220646A1 |
The present invention relates to an improved process for the preparation of (2S)-2- [(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide compound of formula- 1, its intermediates, novel salt compounds of intermediates of the compoun...
|
WO/2018/221604A1 |
The present invention provides a method for industrially producing: a pyrimidine compound having pest control efficacy; 2-[4-(trifluoromethyl)phenyl]ethylamine, which is a production intermediate of the pyrimidine compound; a phenylethyl...
|
WO/2018/214980A1 |
The present invention provides a novel aromatic amide as a Kv2.1 inhibitor and a preparation method, pharmaceutical composition, and use thereof. In particular, the present invention relates to an aromatic amide derivative shown in gener...
|
WO/2018/210274A1 |
Provided is a novel, mild, highly effective, and economic process for co-producing formamide and monofunctional or polyfunctional acrylamide compounds.
|
WO/2018/212216A1 |
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...
|
WO/2018/205299A1 |
Disclosed are a 4,5-disubstituted-1-hydro-pyrrole(2,3-f)quinolone-2,7,9-tric
arboxylate compound, an analogue of same or a derivative of same, the structure thereof is as represented by formula I: where R1 and R4 respectively are indepen...
|
WO/2018/206879A1 |
Process for the synthesis of N-acyl derivatives of amino acids and oligopeptides, without the use of solvents or acid chloride. The invention also relates to cosmetic compositions containing same.
|
WO/2018/206239A1 |
A poly-lysine derivative obtained by a process comprising the steps of (a) heating an aqueous lysine solution to boiling (b) increasing temperature of the aqueous lysine solution to a reaction temperature in the range of about 105°C to ...
|
WO/2018/207120A1 |
The present invention is directed towards a process for the preparation of 4- fluoro-2-methoxy-5-nitroaniline (I) or salts thereof, wherein, 4-fluoro-2-methoxy aniline (III) is protected to obtain N-protected-(4-fiuoro-2-methoxy)aniline ...
|
WO/2018/206758A1 |
A polymeric stabilizing agent selected from poly-lysine derivatives obtained by the process comprising the steps of: I. heating an aqueous lysine solution to boiling II. increasing temperature of the aqueous lysine solution to a reaction...
|
WO/2018/203525A1 |
The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichlo...
|
WO/2018/199147A1 |
Provided is a novel method for producing amide compounds at high stereochemical selectivities. The method according to the present invention for producing amide compounds is provided with an amidation step for reacting, in the presence o...
|
WO/2018/199146A1 |
Provided is a novel method for producing amide compounds at high stereochemical selectivity. This method for producing amide compounds is provided with an amidation step for reacting an aminoester compound represented by general formula ...
|
WO/2018/196812A1 |
Disclosed are a boric acid and borate ester compound, and a preparation method and use therefor. Specifically disclosed are a borate ester compound of formula I, a crystal form, and pharmaceutically acceptable salts, hydrates or solvates...
|
WO/2018/192043A1 |
The present invention pertains to the technical field of herbicide crystallization processes, and particularly relates to a triazolesulcotrione crystal form B, a preparation method therefor, and a use thereof. The triazolesulcotrione cry...
|
WO/2018/177488A1 |
Acrylamide photoinitiators are provided, in which a photoinitiator moiety and an acrylamide are incorporated into the photoinitiator structure.
|
WO/2018/171575A1 |
Substituted aromatic compounds of formula (I) shown below: (formula I) The definition of each variable in formula (I) appears in the Specification. Also disclosed is a pharmaceutical composition containing one of the substituted aromatic...
|
WO/2018/175601A1 |
The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides platinum compounds that are chemically modified to have one or more moieties that include hydrophobic portions. In s...
|
WO/2018/172783A1 |
There is described a method of reducing polymer tar build-up in the production of methyl methacrylate and/or methacrylic acid by the acetone cyanohydrin process. In the method a stabiliser is contacted with the amide stage reaction mediu...
|
WO/2018/166505A1 |
Disclosed are a compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and an application thereof in preventing or treating fatty liver or in preparing weight-reducing drugs.
|
WO/2018/167801A1 |
The present invention disclosed a novel tricyclic compound of formula (I), process for the preparation and use thereof in the treatment of cancer. The present invention further relates to novel compound of formula (II) which is used as i...
|
WO/2018/166504A1 |
Disclosed are a compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the formula I, and an application thereof in preparing drugs for regulating blood lipids.
|
WO/2018/159028A1 |
The present invention provides an industrially excellent production method by which N-benzyl-2-bromo-3-methoxypropionamide can be safely produced in high yield at lower cost. The production method of the present application comprises, in...
|
WO/2018/153364A1 |
Disclosed are an osalmid crystal form II, a preparation method therefor, and applications thereof. An XRPD indicated by an 2θ angle, of the crystal form has characteristic peaks at the diffraction angels 7.527±0.2, 13.653±0.2, 14.644Â...
|
WO/2018/156500A1 |
Methods of synthesizing polyfluorinated amino acid derivatives are disclosed, along with polyfluorinated amino acid derivatives produced from said methods, as well as compositions containing same. The synthesis methods utilize an oxazolo...
|
WO/2018/146285A1 |
The present invention relates to a method for the production of organo-iodinated compounds, as well as the production intermediates thereof. More specifically, the present invention relates to a method for the production of organo-iodina...
|
WO/2018/141276A1 |
Disclosed are a novel crystal form of a brivaracetam intermediate compound (I) and preparation method thereof, and a novel crystal form of brivaracetam and preparation method thereof, specifically a crystal form A of a compound I and a c...
|
WO/2018/144385A1 |
A convenient method for converting oximes into enamides is disclosed. The process produces enamides without the concomitant production of a large volume of metallic waste (I). The enamides are useful precursors to amides and amines.
|
WO/2018/144101A1 |
Described herein are labeling agents, specifically [11C]fluoroform, [11C]difluoromethane, [11C]fluoromethyl iodide, [11C]fluoromethyl bromide, [11C]fluoromethyl chloride, [11C]fluoromethyl trifluoromethansulfonate, [11C]difluoromethyl io...
|
WO/2018/135574A1 |
A method for producing N-(α-hydroxyethyl)formamide which comprises reacting formamide with acetaldehyde in a solvent in the presence of a basic catalyst in a reaction vessel, precipitating the obtained N-(α-hydroxyethyl)formamide in th...
|
WO/2018/132550A1 |
Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium c...
|